NCT06258213View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

July 29, 2024

Study Completion Date

July 29, 2024

Conditions
GoutAcute Gout FlareGout Flares
Interventions
DRUG

ABP-745

0.5, 5 or 25 mg tablet

DRUG

Placebo

Placebo tablet

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Atom Therapeutics Co., Ltd

INDUSTRY

NCT06258213 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers | Biotech Hunter | Biotech Hunter